靶向强化终末病房消毒对全院多重耐药菌和艰难梭菌获得与感染的有效性:BETR消毒多中心交叉整群随机对照试验的二次分析
BETR消毒研究为美国东南部9家医院开展的多中心交叉整群随机对照试验的预设二次分析,评估四种终末消毒策略对全院多重耐药菌和艰难梭菌获得的影响。共314610例次入院纳入分析,标准消毒与三种强化策略间全院目标病原体获得风险无显著差异;UV策略期间艰难梭菌(RR 0.89)和VRE(RR 0.56)获得风险降低。
要点
- 标准消毒与三种强化终末消毒策略间全院多重耐药菌获得风险无显著差异。
- UV策略期间艰难梭菌获得风险RR 0.89(95%CI 0.80-0.99;p=0.031)。
- UV策略期间VRE获得风险RR 0.56(95%CI 0.31-0.996;p=0.048)。
核心结论
- 在高风险病房靶向使用UV强化终末消毒可降低全院艰难梭菌和VRE发生率。
- 强化消毒克服了标准消毒策略的局限性,可能是降低多重耐药菌和艰难梭菌获得风险的潜在策略。
研究设计与样本
- BETR消毒研究为实用型、多中心、交叉整群随机对照试验,在美国东南部9家医院开展。
- 本研究为BETR消毒研究的预设二次分析。
- 四种终末消毒策略按1:1:1:1随机分配顺序,每种策略使用7个月,包括1个月导入期和6个月数据收集期。
- 2012年4月至2014年7月,共271740例独特患者、375918例次入院;314610例次入院符合全部纳入标准(参考期73071例次、UV期81621例次、漂白剂期78760例次、漂白剂联合UV期81158例次)。
主要发现
- 研究期间共发生2681例次医院获得性感染或定植。
- 标准消毒与UV策略间全院目标多重耐药菌获得风险无显著差异(RR 0.89,95%CI 0.79-1.00;p=0.052)。
- 标准消毒与漂白剂策略间无显著差异(RR 0.92,95%CI 0.79-1.08;p=0.32)。
- 标准消毒与漂白剂联合UV策略间无显著差异(RR 0.99,95%CI 0.89-1.11;p=0.89)。
- UV策略期间风险下降由艰难梭菌(RR 0.89,95%CI 0.80-0.99;p=0.031)和VRE(RR 0.56,95%CI 0.31-0.996;p=0.048)获得风险降低驱动。
关键数值与推荐
- 标准消毒:季铵盐消毒剂,艰难梭菌则用10%次氯酸盐(漂白剂)。
- UV策略:标准消毒联合消毒紫外线(UV-C),艰难梭菌则用漂白剂联合UV-C。
- 漂白剂策略:10%次氯酸盐。
- 漂白剂联合UV策略:漂白剂联合UV-C。
- 目标病原体为艰难梭菌、耐甲氧西林金黄色葡萄球菌、耐万古霉素肠球菌(VRE)和多重耐药不动杆菌属。
临床怎么用
- 作者认为,在高风险病房靶向使用UV强化终末消毒是降低多重耐药菌和艰难梭菌获得风险的潜在策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The hospital environment is a source of pathogen transmission. The effect of enhanced disinfection strategies on the hospital-wide incidence of infection has not been investigated in a multicentre, randomised controlled trial. We aimed to assess the effectiveness of four disinfection strategies on hospital-wide incidence of multidrug-resistant organisms and Clostridium difficile in the Benefits of Enhanced Terminal Room (BETR) Disinfection study. METHODS: We did a prespecified secondary analysis of the results from the BETR Disinfection study, a pragmatic, multicentre, crossover cluster-randomised trial that assessed four different strategies for terminal room disinfection in nine hospitals in the southeastern USA. Rooms from which a patient with a specific infection or colonisation (due to the target organisms C difficile, meticillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci (VRE), or multidrug-resistant Acinetobacter spp) was discharged were terminally disinfected with one of four strategies: standard disinfection (quaternary ammonium disinfectant, except for C difficile, for which 10% hypochlorite [bleach] was used; reference); standard disinfection and disinfecting ultraviolet light (UV-C), except for C difficile, for which bleach and UV-C was used (UV strategy); 10% hypochlorite (bleach strategy); and bleach and UV-C (bleach and UV strategy). We randomly assigned the sequence of strategies for each hospital (1:1:1:1), and each strategy was used for 7 months, including a 1-month wash-in period and 6 months of data collection. The prespecified secondary outcomes were hospital-wide, hospital-acquired incidence of all target organisms (calculated as number of patients with hospital-acquired infection with a target organism per 10 000 patient days), and hospital-wide, hospital-acquired incidence of each target organism separately. BETR Disinfection is registered with ClinicalTrials.gov, number NCT01579370. FINDINGS: Between April, 2012, and July, 2014, there were 271 740 unique patients with 375 918 admissions. 314 610 admissions met all inclusion criteria (n=73 071 in the reference study period, n=81 621 in the UV study period, n=78 760 in the bleach study period, and n=81 158 in the bleach and UV study period). 2681 incidenct cases of hospital-acquired infection or colonisation occurred during the study. There was no significant difference in the hospital-wide risk of target organism acquisition between standard disinfection and the three enhanced terminal disinfection strategies for all target multidrug-resistant organisms (UV study period relative risk [RR] 0·89, 95% CI 0·79-1·00; p=0·052; bleach study period 0·92, 0·79-1·08; p=0·32; bleach and UV study period 0·99, 0·89-1·11; p=0·89). The decrease in risk in the UV study period was driven by decreases in risk of acquisition of C difficile (RR 0·89, 95% CI 0·80-0·99; p=0·031) and VRE (0·56, 0·31-0·996; p=0·048). INTERPRETATION: Enhanced terminal room disinfection with UV in a targeted subset of high-risk rooms led to a decrease in hospital-wide incidence of C difficile and VRE. Enhanced disinfection overcomes limitations of standard disinfection strategies and is a potential strategy to reduce the risk of acquisition of multidrug-resistant organisms and C difficile. FUNDING: US Centers for Disease Control and Prevention.
引用
- Anderson DJ, Moehring RW, Weber DJ, et al. Effectiveness of targeted enhanced terminal room disinfection on hospital-wide acquisition and infection with multidrug-resistant organisms and Clostridium difficile: a secondary analysis of a multicentre cluster randomised controlled trial with crossover design (BETR Disinfection). Lancet Infect Dis. 2018. PMID: 29880301. doi:10.1016/S1473-3099(18)30278-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。